After revieving the internactions of lapatinib or trastuzumab in combination with an aromatase inhibitor for metastatic breast cancer patients, NICE has concluded that lapatinib and trastuzumab "do not provide enough benefit to patients to justifty their high costs." Despite special considerations looking at extending lives of people with this cancer, no definite benefits could be found. As a result, does not recommend lapatinib or trastuzumab as a course of treatment.
More information on this guideline can be found here.
No comments:
Post a Comment